News and analysis of Biotech stocks. No buy or sell recommendations.

Visit SeekingAlpha Biotech Stocks

Viropharma, Lev Pharmaceuticals: An Attractive Biotech Pair

Posted on October 09, 2008

Lev Pharmaceuticals (LEVP.OB) is a biotechnology company, which has focused on developing a treatment for the serious, and potentially life-threatening disorder known as hereditary angioedema, which has no FDA approved treatments in the United States. Lev's treatment is known as Cinryze and the company is seeking approval for both acute and prophylactic indications with a PDUFA date of October 14, 2008.In late January 2008, Lev received a complete response letter from the FDA for the acute indication seeking additional information regarding manufacturing, chemistry and controls used in the stu...

Original article link


biotech , biotechnology